Heart/Lung

Aspirin approved as emergency treatment for heart attacks (Dr. Dan Kalla, St. Paul's Hospital)

Doctors have known for more than a decade that chewing an aspirin during a heart attack can dramatically lower the risk of death.

First-in-human transcatheter mitral valve replacement cases show safety, efficacy (Dr. Anson Cheung)

Transcatheter mitral valve replacement may soon be another tool in the interventional toolbox, as highlighted by a first-in-human series demonstrating safety and feasibility in two Canadian patients with severe mitral regurgitation.

Enzyme may be key to stopping fatal sepsis outcomes (Centre for Heart Lung Innovation)

Severe sepsis is an infection from any source that threatens to shut the patient's vital organs down.

Neovasc receives FDA conditional approval to initiate TIARA-I trial in US (Dr. Anson Cheung)

Neovasc Inc. today announced that it has received conditional Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate the U.S. arm of its TIARA-I Early Feasibility Trial for the Company's Tiara™ transcatheter mitral valve.

Virtual rehab program brings heart disease care to rural communities (Dr. Scott Lear)

Living in a small town in this province and trying to manage certain health problems can be difficult for a lot of people.

Young man waiting for a heart transplant has all his medical equipment stolen (Wynne Chiu, St. Paul's Hospital)

A young man from Surrey who is waiting for a life-saving heart transplant had his truck stolen outside of Metrotown in Burnaby this weekend.

Neovasc Reducer™ featured in live case session at TCT 2014 Scientific Symposium (St. Paul's Hospital)

Neovasc Inc. announced today that its Reducer™ technology was featured in a “live case” broadcast on Sunday, September 14, 2014 at the 26th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.  A Clinical update on the company's Tiara™ transcatheter mitral valve (TMVI) program was also presented. TCT is the world's largest educational meeting specializing in interventional cardiovascular medicine and is being held September 13–17, 2014 in Washington, DC.

Urgent call to approve heart failure drug (St. Paul's Hospital, Dr. Andrew Ignaszewski)

An urgent call out to Ottawa to fast-track a potentially lifesaving heart medication. A quick nod from Health Canada could mean the difference between life or death for thousands of patients in BC.

Elaine Yong reports

Click here to view the video

Dr. John Webb—a pioneer in Transcatheter Aortic Valve Implantation

St. Paul's Hospital’s Dr. John Webb stopped in Vancouver just long enough to speak at the Public Salon about the Transcatheter Aortic Valve Implantation Procedure (TAVR), which he teaches in countries around the world. TAVR is a procedure which has shown great results on patients who are high risk for open heart surgery.

Sam Sullivan writes

New heart failure drug could reduce death by 20 per cent, trial shows

A new drug for heart failure could reduce the number of deaths from the disease by 20%, and is the first treatment in two decades to show a higher survival rate for patients, says one of BC’s top cardiologists.

Dr. Andrew Ignaszewski, head of cardiology at St. Paul’s Hospital, is one of the lead researchers into the largest heart failure study to date and was in Spain on Saturday to present the findings at the European Society of Cardiology.

He called the findings a major advancement in heart failure treatment.

Tiffany Crawford reports

Pages

Subscribe to RSS - Heart/Lung